Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468715 · ClinicalTrials.gov registry record · Phase 2
Bicalutamide in Treating Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00468715: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00468715 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00468715, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can cause the growth of breast cancer cells. Antihormone therapy, such as bicalutamide, may stop the adrenal glands from making androgens. PURPOSE: This phase II trial is studying how well bicalutamide works in treating patients with metastatic breast cancer.
Interventions
- OTHER immunohistochemistry staining method
- OTHER diagnostic laboratory biomarker analysis
- DRUG bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-03-23 |
| Est. Completion | 2021-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00468715
The ClinicalTrials.gov registry entry for NCT00468715 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which immunohistochemistry staining method is the first listed.
NCT00468715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00468715 about?
NCT00468715 is a clinical study titled "Bicalutamide in Treating Patients With Metastatic Breast Cancer". RATIONALE: Androgens can cause the growth of breast cancer cells. Antihormone therapy, such as bicalutamide, may stop the adrenal glands from making androgens. PURPOSE: This phase II trial is studying how well bicalutamide works in treating patients with metastatic breast cancer.
What is the current status of trial NCT00468715?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2007-03-23. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT00468715?
The interventions under investigation include: immunohistochemistry staining method (OTHER), diagnostic laboratory biomarker analysis (OTHER), bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00468715?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.